Podcasts about DNA

This episode covers: • Colon Cancer in the Young and Why Risk May Start in Infancy New reporting highlights a troubling rise in early-onset colon cancer, including cases in highly fit endurance athletes. Researchers identified a distinct DNA damage signature linked to colibactin, a toxin produced by certain strains of E. coli, with evidence suggesting the damage may occur in infancy. Dave explains why fitness alone isn't protective, how early-life microbiome disruption and low-fiber modern diets stack long-term risk, and why earlier screening and gut-supportive habits like fiber, resistant starch, and circadian alignment matter more than ever. Source: https://www.businessinsider.com/why-so-many-young-people-getting-colon-cancer-answer-infancy-2025-12 • Kefir-Derived Bacteria, Immune Aging, and the Thymus A mouse study found that a kefir-derived bacterial strain, even when heat-inactivated, reduced age-related thymus shrinkage and lowered inflammatory signaling like IL-6. Dave breaks down why the thymus is central to immune aging, how chronic inflammation accelerates immune decline, and why your immune system responds to microbial signals, not just live probiotics. He explains how consistent fermented foods can act as immune training rather than a one-off supplement strategy. Source: https://economictimes.indiatimes.com/magazines/panache/popular-drink-can-reverse-aging-this-beverage-can-improve-immunity-and-help-achieve-longevity-finds-research/articleshow/126162250.cms • Why Vitamin D Doesn't Work Without Magnesium A human trial shows that magnesium status strongly determines how vitamin D behaves in the body. Magnesium is required for the enzymes that activate vitamin D, and deficiency can block its effects. Dave explains why some people see no improvement despite supplementing vitamin D, how magnesium restored low levels and normalized high ones, and why nutrient networks matter more than megadosing a single vitamin. Source: https://www.sciencedaily.com/releases/2025/12/251228020010.htm • The Selenium Sweet Spot and Mortality Risk A large population analysis found a U-shaped relationship between dietary selenium intake and mortality. Low selenium increased all-cause and cardiovascular mortality, while higher intake offered no additional benefit and may increase risk. Dave explains selenium's role in antioxidant defense, thyroid function, and immunity, why deficiency and excess are both problems, and how to approach selenium as a precision nutrient rather than a blanket supplement. Source: https://www.nature.com/articles/s41598-025-29228-3 • Time-Restricted Eating: Why the Window Matters More Than the Meal A randomized controlled trial compared early time-restricted eating, late time-restricted eating, and unrestricted eating. Both time-restricted groups naturally ate fewer calories without dieting, mainly by reducing snacking, while the unrestricted group drifted upward. Dave explains why the real benefit isn't metabolic magic but behavioral control, how eating windows reduce decision fatigue and metabolic noise, and why consistency beats perfection when using time-restricted eating as a long-term tool. Source: https://www.nature.com/articles/s41467-022-28662-5 Keywords: early onset colon cancer, colon cancer in young adults, gut microbiome infancy, colibactin E. coli, precancerous colon polyps, fiber and colon health, kefir immune aging, fermented foods immunity, thymus aging, T-cell decline aging, IL-6 chronic inflammation, immune resilience longevity, vitamin D magnesium interaction, magnesium deficiency vitamin D, nutrient cofactor metabolism, vitamin D activation enzymes, selenium intake mortality, selenium deficiency risk, selenium over supplementation, antioxidant enzymes selenium, time restricted eating study, eating window metabolism, skip breakfast vs skip dinner, circadian eating patterns, behavioral calorie reduction, metabolic health biohacking, longevity science news Thank you to our sponsors! - BEYOND Conference 2026 | Register now at https://beyondconference.com/ -Timeline | Go to http://timeline.com/dave and get 35% off a subscription with their New Year offer. Resources: • Subscribe to my weekly newsletter: https://substack.daveasprey.com/welcome • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Upgrade Collective: https://www.ourupgradecollective.com • Upgrade Labs: https://upgradelabs.com • 40 Years of Zen: https://40yearsofzen.com Timestamps: 0:00 – Intro 0:18 – Story #1: Colon Cancer in Young Athletes 1:40 – Story #2: Immune Aging and Microbial Signals 2:48 – Story #3: Vitamin D and Magnesium Connection 4:31 – Story #4: Selenium Sweet Spot 5:27 – Story #5: Time-Restricted Eating 6:56 – Weekly Upgrade Protocol 7:40 – Outro See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

"We proposed a concept to the American Society of Clinical Oncology (ASCO), recognizing that extravasation management requires significant interdisciplinary collaboration and rapid action. There can occasionally be uncertainty or lack of clear guidance when an extravasation event occurs, and our objective was to look at this evidence with the expert panel to create a resource to support oncology teams overall. We hope that the guideline can help mitigate harm and improve patient outcomes," Caroline Clark, MSN, APRN, AGCNS-BC, OCN®, EBP-C, director of guidelines and quality at ONS, told Chelsea Backler, MSN, APRN, AGCNS-BC, AOCNS®, VA-BC, oncology clinical specialist at ONS, during a conversation about the ONS/ASCO Guideline on the Management of Antineoplastic Extravasation. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by January 2, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the management of antineoplastic extravasation. Episode Notes  Complete this evaluation for free NCPD. ONS/ASCO Guideline on the Management of Antineoplastic Extravasation ONS Podcast™ episodes: Episode 391: Pharmacology 101: Antibody–Drug Conjugates Episode 335: Ultrasound-Guided IV Placement in the Oncology Setting Episode 145: Administer Taxane Chemotherapies With Confidence Episode 127: Reduce and Manage Extravasations When Administering Cancer Treatments ONS Voice articles: Access Devices and Central Lines: New Evidence and Innovations Are Changing Practice, but Individual Patient Needs Always Come First New Extravasation Guidelines Provide Recommendations for Protecting Patients and Standardizing Care Standardizing Venous Access Assessment and Validating Safe Chemo Administration Drastically Lowers Rates of Adverse Venous Events This Organization's Program Trains Non-Oncology Nurses to Deliver Antineoplastic Agents Safely ONS books: Access Device Guidelines: Recommendations for Nursing Practice and Education (fourth edition) Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) ONS courses: Complications of Vascular Access Devices (VAD) and IV Therapy ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ ONS Oncology Treatment Modalities Clinical Journal of Oncology Nursing articles: Chemotherapy Extravasation: Incidence of and Factors Associated With Events in a Community Cancer Center Standardized Venous Access Assessment and Safe Chemotherapy Administration to Reduce Adverse Venous Events Oncology Nursing Forum article: Management of Extravasation of Antineoplastic Agents in Patients Undergoing Treatment for Cancer: A Systematic Review ONS huddle cards: Antineoplastic Administration Chemotherapy Immunotherapy Implanted Venous Port ONS position statements: Administration (Infusion and Injection) of Antineoplastic Therapies in the Home Education of the Nurse Who Administers and Cares for the Individual Receiving Antineoplastic Therapies ONS Guidelines™ for Extravasation Management ONS Oncologic Emergencies Learning Library ONS/ASCO Algorithm on the Management of Antineoplastic Extravasation of Vesicant or Irritant With Vesicant Properties in Adults American Society of Clinical Oncology (ASCO) Podcast: Management of Antineoplastic Extravasation: ONS-ASCO Guideline To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "The focus of this guideline was specifically on intravenous antineoplastic extravasation or when a vesicant or an irritant with vesicant properties leaks out of the vascular space. This can cause an injury to the patient that's influenced by several factors including the specific drug that was involved in the extravasation, whether it was DNA binding, how much extravasated, the affected area, and individual patient characteristics." TS 1:48 "The panel identified and ranked outcomes that mattered most with extravasation. Not surprising, one of the first was tissue necrosis. Like, 'How are we going to prevent tissue necrosis and preserve tissue?' The next were pain, quality of life, delays in cancer treatment: How is an extravasation going to delay cancer treatment that's vital to the patient? Is an extravasation also going to result in hospitalization or additional surgical interventions that would be burdensome to the patient? ... We had a systematic review team that then went in and summarized the data, and the panel applied the grading of recommendations, assessment, development, and evaluation (GRADE) criteria, grading quality of evidence and weighing factors like patient preferences, cost, and feasibility of an intervention. From there, they developed their recommendations." TS 7:35 "The panel, from the onset, wanted to make sure we had something visual for our readers to reference. They combined evidence from the systematic review, other scholarly sources, and their real-world clinical experience to make this one-page supplementary algorithm. They wanted it to be comprehensive and easy to follow, and they included not only those acute management steps but also guidance on 'How do I document this and what are the objective and subjective assessment factors to look at? What am I going to tell the patient?' In practice, for use of that, I would compare it to your current processes and identify any gaps to inform policies in your individual organizations." TS 16:34 "The guidelines don't take place of clinician expertise; they're not intended to cover every situation, but a situation that keeps coming up that we should talk about as a limitation, is we're seeing these case reports of tissue injury with antibody–drug conjugate extravasation. There's still not enough evidence to inform care around the use of antidotes with those agents, so this still needs to be addressed on a case-by-case basis. We still need publication of those case studies, what was done, and outcomes to help inform direction." TS 19:24 "Beyond the acute management is to ensure thorough documentation regarding extravasation. Whether you're on electronic documentation or on paper, are the prompts there for the nurse to capture all of the factors that should be captured regarding that extravasation? The size, the measurement, the patient's complaints. Is there redness? Things like that. And then within the teams, everyone should know where to find that initial extravasation assessment so that later on, if they're in a different clinic, they have something to go by to see how the extravasation is healing or progressing. ... I think there's an importance here, too, to our novice oncology nurses and their preceptors. This could be anxiety-provoking for the whole team and the patient, so we want to increase confidence in management. So, I think using these resources for onboarding novice oncology nurses is important." TS 22:34

Forty years after 22-year-old Kelly Jean Robinson was found floating in a gravel pit pond in rural Minnesota, her case had gone cold — until DNA tests taken by an adopted man revealed that Kelly was his biological mother, and she had been murdered. In this episode, Dakota Spotlight is excited to share this story from our longtime friend Trisha Taurinskas. Her investigative reporting is meticulous, insightful, and deeply respectful of the families she covers. Working with Kelly's family, Trisha uncovered never-before-released information: new suspects, details from her autopsy, and new critical facts from an autopsy. To see images of Kelly, visit: https://www.inforum.com/people/kelly-robinson Check out the full catalog and everything Dakota Spotlight: https://dakotaspotlight.com/ Get all episodes early, ad-free, and more. Subscribe to Spotlight PLUS: https://dakotaspotlight.com/spotlight-plus/ Sign up for the Dakota Spotlight newsletter: https://dakotaspotlight.com/newsletter/ Email: dakotaspotlight@gmail.com Facebook: https://facebook.com/groups/dakotaspotlight X/Twitter: @dakotaspotlight Instagram: @dakotaspotlight TikTok: @dakotaspotlight Bluesky: @dakotaspotlight.bsky.social YouTube: @dakotaspotlightpodcast4800 Proudly produced by Six Horse Media: info@sixhorsemedia.com Advertise your podcast or brand in Dakota Spotlight episodes: info@sixhorsemedia.com All content in this podcast, including audio, interviews, and soundscapes, is the property of Six Horse Media. Any unauthorized use, reproduction, or rebroadcast of this material without the express written consent of Six Horse Media is strictly prohibited. For permissions or inquiries, please contact info@sixhorsemedia.com. Learn more about your ad choices. Visit podcastchoices.com/adchoices

The façade of the “sweet grandmother in a cardigan” shattered today. In this hard-hitting Hidden Killers breakdown, we walk through nine of the most devastating revelations from Sergeant Christopher Corbett's testimony — evidence so precise, so digital, and so tightly woven that it left the courtroom stunned. These weren't theories. These weren't assumptions. These were time-stamped movements, call patterns, incriminating texts, and Donna Adelson's own words, laid out with forensic clarity. Among the biggest blows: • The “Outside your house” text. A message sent at the exact moment prosecutors say Donna was tracking Dan Markel's movements. • “Erase this after you read it.” A chilling instruction no innocent person casually sends. • Charlie's perfectly timed calls — aligning almost to the minute with rental car pickups tied to the hit. • Donna's movements minutes after the murder, including a route that conveniently took her past Charlie's house. • Calling the Markel children “Adelsons” two weeks before Dan was killed, revealing a mindset prosecutors say exposes motive. • A 2013 email laying out a coordinated plan involving Donna, Harvey, and Charlie — to corner, pressure, and financially squeeze Dan. A blueprint prosecutors argue became the DNA of the murder plot. Corbett's testimony destroyed any illusion that this was mere “family conflict.” The jury saw a digital trail of coordination, secrecy, and intent — breadcrumb after breadcrumb pointing straight toward Donna. This episode breaks down each bombshell moment in plain language, showing how the prosecution connected Donna's texts, location data, phone records, and long-running resentments into a narrative that's now impossible to ignore. Listen closely. These weren't harmless family conversations. They were signals, timing cues, and cover stories — the anatomy of a conspiracy unraveling in real time. #DonnaAdelson #DanMarkel #AdelsonTrial #MurderForHire #CharlieAdelson #TrueCrime #WiretapEvidence #CourtroomDrama #HiddenKillers #PhoneRecords #CrimeAnalysis Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/@hiddenkillerspod Instagram https://www.instagram.com/hiddenkillerspod/ Facebook https://www.facebook.com/hiddenkillerspod/ Tik-Tok https://www.tiktok.com/@hiddenkillerspod X Twitter https://x.com/tonybpod Listen Ad-Free On Apple Podcasts Here: https://podcasts.apple.com/us/podcast/true-crime-today-premium-plus-ad-free-advance-episode/id1705422872

This episode of the No Film School Podcast features two deep and distinct conversations. First, host GG Hawkins reunites with filmmaker Pete Ohs, who returns to share the unique distribution experiment he's launching with four films releasing throughout 2026. He reflects on his “table of bubbles” filmmaking philosophy and his desire to find joy instead of stress in the release process. Later, GG is joined by composer Hollie Buhagiar, whose original score for GG's debut feature I Really Love My Husband is now out. They break down their collaborative process in detail, from early cue drafts to the film's final emotional moments, revealing how bird calls, pitch-shifted vocals, and “surf rock” found their way into the film's DNA. In this episode, No Film School's GG Hawkins and guests discuss... Pete Ohs' philosophy of “table of bubbles” and how it's guiding his 2026 film distribution approach Why Pete is using a different distribution strategy for each of his four new films What feels broken about indie film distribution today — and how to approach it differently Hollie Buhagiar's journey into composing and her intuitive, emotion-driven scoring method The evolution of the score for I Really Love My Husband, including early drafts and final cues How creative freedom, happy accidents, and imperfect instruments brought the film to life The importance of developing a shared language between director and composer Memorable Quotes: "The films are a table made of bubbles. They cannot support anything." "The biggest result is just — is this fun?" "What's a convincing note?” "With great power comes great responsibility — even for the piano." Guests: Pete Ohs Hollie Buhagiar Resources: Pete's original pod interview Score for I Really Love My Husband on Spotify Find No Film School everywhere: On the Web: No Film School Facebook: No Film School on Facebook Twitter: No Film School on Twitter YouTube: No Film School on YouTube Instagram: No Film School on Instagram

The façade of the “sweet grandmother in a cardigan” shattered today. In this hard-hitting Hidden Killers breakdown, we walk through nine of the most devastating revelations from Sergeant Christopher Corbett's testimony — evidence so precise, so digital, and so tightly woven that it left the courtroom stunned. These weren't theories. These weren't assumptions. These were time-stamped movements, call patterns, incriminating texts, and Donna Adelson's own words, laid out with forensic clarity. Among the biggest blows: • The “Outside your house” text. A message sent at the exact moment prosecutors say Donna was tracking Dan Markel's movements. • “Erase this after you read it.” A chilling instruction no innocent person casually sends. • Charlie's perfectly timed calls — aligning almost to the minute with rental car pickups tied to the hit. • Donna's movements minutes after the murder, including a route that conveniently took her past Charlie's house. • Calling the Markel children “Adelsons” two weeks before Dan was killed, revealing a mindset prosecutors say exposes motive. • A 2013 email laying out a coordinated plan involving Donna, Harvey, and Charlie — to corner, pressure, and financially squeeze Dan. A blueprint prosecutors argue became the DNA of the murder plot. Corbett's testimony destroyed any illusion that this was mere “family conflict.” The jury saw a digital trail of coordination, secrecy, and intent — breadcrumb after breadcrumb pointing straight toward Donna. This episode breaks down each bombshell moment in plain language, showing how the prosecution connected Donna's texts, location data, phone records, and long-running resentments into a narrative that's now impossible to ignore. Listen closely. These weren't harmless family conversations. They were signals, timing cues, and cover stories — the anatomy of a conspiracy unraveling in real time. #DonnaAdelson #DanMarkel #AdelsonTrial #MurderForHire #CharlieAdelson #TrueCrime #WiretapEvidence #CourtroomDrama #HiddenKillers #PhoneRecords #CrimeAnalysis Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/@hiddenkillerspod Instagram https://www.instagram.com/hiddenkillerspod/ Facebook https://www.facebook.com/hiddenkillerspod/ Tik-Tok https://www.tiktok.com/@hiddenkillerspod X Twitter https://x.com/tonybpod Listen Ad-Free On Apple Podcasts Here: https://podcasts.apple.com/us/podcast/true-crime-today-premium-plus-ad-free-advance-episode/id1705422872

FREE 2026 Astrology Deep Dive — grounded, embodied insight into the archetypal forces shaping 2026 — and how they are meant to move through your body, choices, and lived experience. This is astrology translated out of theory and into real life. →  Access here   We begin 2026 under a powerful Jan 1 astrology chart and a Full SuperMoon in Cancer, setting the emotional and physical tone for the year ahead. This is a year of deep reconfiguration — where energetic shifts finally begin to land in the body, in relationships, and in the world around us. The January 1, 2026 astrology chart opens a powerful new chapter as the Full SuperMoon in Cancer illuminates Sacred Union between Masculine and Feminine, deep emotional healing, and the physical arrival of long-awaited energetic shifts. This episode explores DNA transmutation, collapsing power structures, Lilith on the North Node, and why 2026 marks the moment the New Earth becomes tangible—inviting you into greater embodiment, discernment, and inner harmony as reality itself begins to reconfigure. Episode Highlights Jan 1 Astrology Portal: a new epoch of conscious, embodied choice begins Sacred Union Activates: masculine–feminine harmony unlocks creation DNA Transmutation: multidimensional awareness enters the body Full Super Moon in Cancer: emotional healing and womb wisdom rise Power Reconfigures: old systems fall as inner sovereignty grows Get the FREE 2026 Astrology Deep Dive This grounded, embodied insight into the archetypal forces shaping 2026 — and how those forces are meant to live through your body, relationships, and choices. Rather than predicting the future, this deep dive reveals how the year's astrology is already activating within you. This is astrology translated into lived experience, guiding you to meet 2026 with clarity, embodiment, and inner authority. → Access here  Listen to “This Year Is Different | 2026 Astrology (Jan 1–4)“ podcast here… Topics Explored in “This Year Is Different | 2026 Astrology (Jan 1–4)” podcast: (Times based off audio version) (0:00) 2026 Astrology Forecast | New Earth Expansion + Reality Shift (4:59) January 1 Chart: 2026 as a “Container” | The Year Imprint & Signpost Energetics (7:07) North Node in Pisces + Lilith | Destiny = Feminine Reclaimed + Consciousness Growth (12:54) Venus–Sun–Sophia–Mars in Capricorn | Union Codes + Creation Portal (19:32) Lilith's Teaching: Equality | What Are You Demonizing in the Feminine? (24:27) Uranus–Osiris–Algol + Medusa/Shiva | Masculine Death/Rebirth + “Heads Will Roll” (36:46) Chiron–Eris + Pele (Jupiter T-Square) | Wounds → Fertile Ground + Initiation (41:30) Mercury–Merlin Opposite Hygeia | Sorcerer Mind + Miraculous Healing/Upgrade (45:27) Archetype IX Mystery School | Embodied Activations for 2026 (47:59) Jan 3 Cancer Supermoon | Great Mother, Womb Wisdom + Discernment (56:21) Priestess/Lightworker in the New Epoch | Channeling Grace Is Different Now You can leave a comment or question for Sabrina on the YouTube version of this episode. Listen to after “This Year Is Different | 2026 Astrology (Jan 1–4)“: 2025's Final Portal | Dec 22–31 Astrology  Snake to Horse Portal Episode Watch Part 1 — “Are You in the First Wave?”  Watch Part 2 – “2025 Consciousness Shift Explained“ STAY CONNECTED ReWilding Weekly (free, embodied astrology)  IG  Website  Disclaimer: Educational/spiritual perspectives; not medical/mental-health advice. #2025Shift #NewHuman #SpiritualAwakening Welcome to ReWilding with Sabrina Lynn & ReWilding for Women! A gifted facilitator of revolutionary inner work and the world's leading archetypal embodiment expert, Sabrina Lynn is the creator of the groundbreaking ReWilding Way and founder of ReWilding For Women. Sabrina has led more than 100,000 people through programs based on the ReWilding Way, a modality of healing and awakening that strips away the false, the deep wounds from early life, and the fears that hold people back, to reveal their true and unique soul light and help them build their innate capacity to shine it in the world. Her work includes in-person retreats and events, the monthly ReWilding Membership, Living Close to the Bone, Priest/ess Trainings, Mystery Schools, the ReWilding with the Archetypes, and the wildly popular 6 Faces of the Feminine workshop series. Welcome to ReWilding! The post 357 – This Year Is Different | 2026 Astrology & the Great Reconfiguration (Jan 1–4) appeared first on Rewilding for Women.

Timestamps: 0:00 'tech' - he's saying 'tech' 0:06 Nvidia GPUs possible price hike 1:55 GameSir Swift Drive, OneXSugar Wallet 4:26 QUICK BITS INTRO 4:37 RX 9070 XT connector burned 5:22 GOG acquired by original co-founder 6:09 China's 50% rule for chip equipment 6:52 Florida's chargin' freakin' roadways 7:34 Wireless brain "implant" 8:02 First scalable DNA data storage NEWS SOURCES: https://lmg.gg/p0WaI Learn more about your ad choices. Visit megaphone.fm/adchoices

What happens when you've done everything right, hit the milestones, followed the plan, built the “good life” and still feel like something's missing? In this week's episode, I'm joined by transformational coach and spiritual mentor Hélène Caniac for a powerful conversation about what it really means to move from achievement to fulfillment. Together, we explore the embodied, lived-in practice of self-trust, pleasure, and presence; how to sustain your power and purpose without burning out or betraying yourself.We dive deep into the systems that have systemically severed our self-trust, from capitalism and productivity culture to patriarchal conditioning and the ways spirituality itself can become another form of performance. Hélène unpacks how disconnection has been woven into our collective DNA for generations, and why rebuilding trust with ourselves is one of the most radical, world-changing acts we can take.If you've been craving a softer, truer way of living, a way that honors both your depth and your belonging, this episode will feel like a homecoming.In this episode, we explore:The shift from achievement to fulfillment — how to move beyond external success and create a life rooted in alignment, joy, and embodied purpose.The systems that sever our self-trust — unpacking how patriarchy, capitalism, and performance-driven spirituality keep us disconnected from our power.Expanding capacity for joy and freedom — practical tools to cultivate presence, discernment, and nervous-system resilience through seasons of chaos or change.Pleasure as a path of leadership — how enjoyment, play, and authenticity become fuel for purpose, creativity, and sustainable impact.Embodiment in everyday life — living your spirituality “in traffic,” in your relationships, and in the ordinary rhythms of work, motherhood, and leadership.Redefining success — shifting from output and performance toward integrity, connection, and fulfillment that actually feels good in your body.The power of collective healing — remembering that true transformation happens in relationship, through community, curiosity, and shared humanity.Be sure to hit subscribe so you never miss the latest episode!Connect with Hélène Caniac:Website: helenecanhelp.comInstagram: @helenecanhelpJoin Le Salon — Hélène's free Telegram community for thought-provoking seasonal musings, voice-note journal prompts, and early access to upcoming offerings. It's a soft place to land for ambitious souls unlearning the hustle and returning to embodied fulfillment.Connect with Emily:Website: www.EmilyReuschel.comInstagram: @emilyreuschelFacebook: Emily ReuschelLinkedIn: Emily ReuschelJoin my Book Insiders List: Sign up...

Du er tunet ind på en ny sæson af Forhjulslir anno 2026, som igen i denne sæson præsenteres af World Tourens mest vindende dæk fra Continental. En god tredjedel af World Tour-feltet kører i 2026 på Continental dæk - naturligvis også verdens bedste cykelrytter fra i fjor, Tadej Pogacar. Sikkerhed starter med dækket. Godt nytår! Så er vi der næsten. Cykelsæsonen 2026. Om bare 20 dage starter det første World Tour-etapeløb Tour Down Under og kort efter vågner de europæiske landeveje op. Det er blevet den 1. januar 2026. En ny sæson står for døren og dermed de nye ændringer, man skal vænne sig til. Nye ryttere i nye trøjer, nye talenter på nye cykler og selvfølgelig rytterne – og det er herrerytterne og herreholdene, vi sætter fokus på i dag. Vi gennemgår alle de 18 World Tour-hold og de bedste Pro Tour Hold, som vi finder i cykelfeltet 2026 - nogle er nye, nogle har skiftet navn og andre har skiftet DNA og udtryk. Vi kigger på de nye ryttertilgange på hvert hold og diskuterer os frem til, hvilke forventninger vi har til det givne hold og dets ryttere. Og naturligvis de danske ryttere, hvor vi i 2026 har hele 28 danskere på herrenes World Tour. Med de ord, godt nytår, glædelig bag(h)jul og velkommen ind på viften af sæson 8 af Forhjulslir og årets første etape: "Den Store Transfergennemgang 2026". Medvirkende: Per Bausager, Emil Mielke Vinjebo & Anders Mielke

► We Get Around Network Forum (https://www.WGANForum.com) --- We Get Around Network Acquired by Tom Sparks from Founder Dan Smigrod  After more than a decade as founder, managing editor, and publisher of the We Get Around Network, Dan Smigrod announces the next chapter in WGAN's history. Effective January 1, 2026, ownership of We Get Around Network has transitioned to long-time WGAN member and contributor Tom Sparks, Principal of Sparks Media Group, through WGAN Holdings Inc. Tom is now the owner, managing editor, and publisher of We Get Around Network—and the new host of the WGAN-TV Podcast. This is a change in leadership, not a change in DNA. Everything the community relies on remains in place: ► The WGAN Forum and its 100,000+ posts ► WGAN-TV Podcast and WGAN-TV Training U ► WGAN MarketPlace and Marketing Partner programs ► Find a Service Provider Map ► Existing memberships, subscriptions, logins, and content WGAN continues to be the trusted, cross-platform knowledge base for digital twins, 3D/360 cameras, real estate media, and the tools and services professionals use every day. Why Tom Sparks Tom is a working real estate photographer and media business owner who actively uses Matterport, iGUIDE, Giraffe360, InnoDraw, SIMLAB, InsideMaps, and related platforms in the field. He brings hands-on experience, editorial credibility, and operational leadership—combined with a clear vision to expand education, deepen technical coverage, and grow vendor partnerships. What's Next Under Tom's leadership, WGAN will: ► Expand practical, field-tested content ► Strengthen marketing partner programs ► Go deeper into digital twins and AI-driven workflows ► Continue delivering trusted insights that help members succeed faster Dan Smigrod's Next Chapter Dan transitions into an advisor role to support a smooth handoff and knowledge transfer. While stepping back from daily publishing, he will continue to appear for select projects, special episodes, and deep dives—while finally reclaiming time for travel, creativity, and exploration in AI and robotics. Join the Conversation Please welcome Tom Sparks as the new publisher of We Get Around Network. Introduce yourself in the WGAN Forum. Share what topics, tools, and technologies you want covered next. The mission remains the same: Give help. Get help. Build the future of digital twins and real estate media—together. Happy New Year,   Dan Smigrod Founder and Advisor We Get Around Network Atlanta  

Björn Schumacher ist einer der profiliertesten Alternsforscher. Im Gespräch geht es um die tiefgreifenden biologischen Mechanismen hinter dem Altern, ethische Grenzen bei der Lebensverlängerung und um sinnvolle Strategien, länger gesund zu leben. (00:00:49) Begrüßung (00:01:55) Vorstellung Björn Schumacher (00:03:37) Warum altern wir? (00:07:36) Was passiert auf der molekularen Ebene? (00:13:23) Reparatur der DNA (00:16:33) Der Alterungsprozess beim Fadenwurm (00:21:23) Weniger essen, gesünder älter werden? (00:25:50) Tipps für ein gesundes Leben (00:30:13) Haut, Anti-Aging und UV-Strahlung (00:32:49) Faktor: sozioökonomischer Status (00:34:50) Der älteste Mensch der Welt (00:46:01) Die Alternsuhr (00:55:37) Die Lebenserwartung (00:58:30) Die Alternsforschung (01:02:48) Das Assoziationsspiel (01:06:05) Medikamente für ein langes Leben? (01:11:44) Der persönliche Weg zur Alternsforschung (01:15:28) Ewiges Leben und das Sterben (01:22:11) Ethische Grenzen (01:24:02) Visionen und falsche Versprechen (01:29:20) Die Spektrum-Zukunftsmaschine (01:32:49) Resümee und Verabschiedung LINKS: Mehr zum Thema Langlebigkeit lest ihr hier im Spektrum Kompakt „Altern“. Hier geht’s zum Artikel „Das Geheimnis der Methusalem-Tiere“Hier lest ihr den Fachartikel zu Björn Schumachers „Alternsuhr“. >> Artikel zum Nachlesen: https://detektor.fm/wissen/die-grossen-fragen-der-wissenschaft-bjoern-schumacher-ewiges-leben

Greetings, and welcome to this podcast. The central theme of this podcast is to align our DNA, regardless of what transpired last year. We can actually derive a benefit that will positively impact the new year. By assisting our DNA in producing Happy RNA, we can enhance our emotional well-being, which, in turn, can influence future events. Scientific research has demonstrated that our emotions play a crucial role in shaping our future.

Greetings, and welcome to this podcast. The central theme of this podcast is to align our DNA, regardless of what transpired last year. We can actually derive a benefit that will positively impact the new year. By assisting our DNA in producing Happy RNA, we can enhance our emotional well-being, which, in turn, can influence future events. Scientific research has demonstrated that our emotions play a crucial role in shaping our future.

Click to Subscribe: https://bit.ly/Youtube-Subscribe-SoapDirt General Hospital spoilers for Jan 5 - 9, 2026 suggest Alexis Davis (Nancy Lee Grahn) sets her sights on Michael Corinthos (Rory Gibson), while viewers are treated to a poignant replay of Luke Spencer's (Anthony Geary) final farewell. Also, as Charlotte Cassadine (Bluesy Burke) and Lulu Spencer (Alexa Havins) find themselves in a tight spot in Prague, Alexis Davis must rethink her strategies after catching wind of Michael's presence at Drew Cain Quartermaine's (Cameron Mathison) house on the night of his shooting. Laura Spencer (Genie Francis) is given a new task, possibly by Ulrich Sidwell (Carlo Rota), and Sonny Corinthos (Maurice Benard) issues a warning to Michael. GH spoilers indicate Portia Robinson (Brook Kerr) is faced with pressure from Curtis Ashford (Donnell Turner) to complete a DNA test, while Carly Corinthos Spencer (Laura Wright) and Valentin Cassadine (James Patrick Stuart) need to step up their game in their scheming against Jasper Jacks [Jax] (Ingo Rademacher).  Spoilers for General Hospital anticipate the identity of Drew's shooter will be revealed, leading to an unexpected twist. Brennan (Charles Mesure), who played a key role in Britt Westbourne (Kelly Thiebaud) regaining her medical license, is expected to make an appearance and demand a favor. Fans can also expect more revelations about Anna Devane (Finola Hughes), and Sonny and Laura's plans to take down Sidwell the week of 01/05 - 01/09/2026. This episode was hosted by Belynda Gates-Turner for the #1 Soap Opera Channel, Soap Dirt. Visit our General Hospital section of Soap Dirt: https://soapdirt.com/category/general-hospital/ Listen to our Podcasts: https://soapdirt.podbean.com/ Check out our always up-to-date General Hospital Spoilers page at: https://soapdirt.com/general-hospital-spoilers/ Check Out our Social Media... Twitter: https://twitter.com/SoapDirtTV Facebook: https://www.facebook.com/SoapDirt Pinterest: https://www.pinterest.com/soapdirt/ TikTok: https://www.tiktok.com/@soapdirt Instagram: https://www.instagram.com/soapdirt/

Björn Schumacher ist einer der profiliertesten Alternsforscher. Im Gespräch geht es um die tiefgreifenden biologischen Mechanismen hinter dem Altern, ethische Grenzen bei der Lebensverlängerung und um sinnvolle Strategien, länger gesund zu leben. (00:00:49) Begrüßung (00:01:55) Vorstellung Björn Schumacher (00:03:37) Warum altern wir? (00:07:36) Was passiert auf der molekularen Ebene? (00:13:23) Reparatur der DNA (00:16:33) Der Alterungsprozess beim Fadenwurm (00:21:23) Weniger essen, gesünder älter werden? (00:25:50) Tipps für ein gesundes Leben (00:30:13) Haut, Anti-Aging und UV-Strahlung (00:32:49) Faktor: sozioökonomischer Status (00:34:50) Der älteste Mensch der Welt (00:46:01) Die Alternsuhr (00:55:37) Die Lebenserwartung (00:58:30) Die Alternsforschung (01:02:48) Das Assoziationsspiel (01:06:05) Medikamente für ein langes Leben? (01:11:44) Der persönliche Weg zur Alternsforschung (01:15:28) Ewiges Leben und das Sterben (01:22:11) Ethische Grenzen (01:24:02) Visionen und falsche Versprechen (01:29:20) Die Spektrum-Zukunftsmaschine (01:32:49) Resümee und Verabschiedung LINKS: Mehr zum Thema Langlebigkeit lest ihr hier im Spektrum Kompakt „Altern“. Hier geht’s zum Artikel „Das Geheimnis der Methusalem-Tiere“Hier lest ihr den Fachartikel zu Björn Schumachers „Alternsuhr“. >> Artikel zum Nachlesen: https://detektor.fm/wissen/die-grossen-fragen-der-wissenschaft-bjoern-schumacher-ewiges-leben

Crime Week continues, as Megyn Kelly is joined by private investigator Steve Ridge to discuss the mysterious Jodi Huisentruit disappearance 30 years ago, Huisentruit's background as a local news anchor, the circumstances of her last night, potential suspects for who could have abducted Huisentruit, why John Vansice was never ruled out as a suspect, the crime scene and evidence gathered at the Huisentruit disappearance, the lack of DNA and cameras back in 1995, the efforts by Ridge to get certain evidence unsealed in the cold case, and more. Find more about the disappearance here: https://findjodi.com/ Byrna: Go to https://Byrna.com or your local Sportsman's Warehouse today.Riverbend Ranch: Visit https://riverbendranch.com/ | Use promo code MEGYN for $20 off your first order.Pendragon Cycle (Daily Wire+): Discover The Pendragon Cycle: Rise of The Merlin—a bold retelling of the King Arthur legend where Merlin's vision sparks a civilization's rebirth; watch the full trailer now at https://pendragonseries.com.  Follow The Megyn Kelly Show on all social platforms:YouTube: https://www.youtube.com/MegynKellyTwitter: http://Twitter.com/MegynKellyShowInstagram: http://Instagram.com/MegynKellyShowFacebook: http://Facebook.com/MegynKellyShow Find out more information at:https://www.devilmaycaremedia.com/megynkellyshow Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Our card this week is Debra Espey, the 6 of Clubs from Florida. Debra Espey was the 6 of Clubs from Florida. We first reported on her case in 2024, and left you all on the precipice of hope that new DNA testing would finally shed light on what happened to a young girl in Niceville over 50 years ago. Well, the results are in! And Debra's case is SOLVED. It turns out her killer was hiding in plain sight, the entire time. In our original reporting, police told us they thought the man responsible for Debra's murder also killed 19-year-old Theresa Dusevitch. But DNA has now proven they aren't connected. Which means our team went back to Theresa's case with fresh eyes. And we'll be bringing you a brand-new story about her, the Queen of Diamonds from Florida. View source material and photos for this episode at: thedeckpodcast.com/remembering-debra-espeyLet us deal you in… follow The Deck on social media.Instagram: @thedeckpodcast | @audiochuckTwitter: @thedeckpodcast_ | @audiochuckFacebook: /TheDeckPodcast | /audiochuckllcTo support Season of Justice and learn more, please visit seasonofjustice.org.The Deck is hosted by Ashley Flowers. Instagram: @ashleyflowersTikTok: @ashleyflowerscrimejunkieTwitter: @Ash_FlowersFacebook: /AshleyFlowers.AFText Ashley at 317-733-7485 to talk all things true crime, get behind the scenes updates, and more! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

New airport rules now allow U.S. officials to collect biometric data from non-citizens, including facial recognition and, in some cases, DNA. The PBD Podcast debates where security ends and surveillance begins, the privacy risks, and whether these measures protect borders or push America closer to a surveillance state.

2025 was another exciting year in human origins research! In this episode, four scientists and Leakey Foundation grantees (and one podcast host) share their picks for the top discoveries of the year. Support this show and the science we talk about. Your tax-deductible gift to The Leakey Foundation will be matched! Click here to donate.  Want more science between podcast episodes? Join our monthly newsletter for human origins news and updates from Origin Stories and The Leakey Foundation. Links to learn more All research articles are open-access and free to read New research reveals the hand of Paranthropus boisei Earliest evidence of making fire Complete sequencing of ape genomes Highly selective cannibalism in the Late Pleistocene of Northern Europe reveals Neandertals were targeted prey Denisovan mitochondrial DNA from dental calculus of the >146,000-year-old Harbin cranium

In this powerful Hidden Killers episode, we examine two sides of the same story: the forensic reality that dismantled Bryan Kohberger's image of intelligence — and the viral victim impact statement that attacked the last thing he had left: his ego. Host Tony Brueski and retired FBI Special Agent Robin Dreeke take you inside the psychology, behavior, and unraveling facade of a man who once believed he could outsmart everyone. First, we break down Alivea Goncalves' extraordinary statement — a surgical strike aimed directly at Kohberger's psychological pressure points. Her words didn't just describe loss. They deconstructed him. She went after his academic identity, his obsession with control, his need to be seen as superior. For someone built entirely around ego, this was a rare moment where the mask slipped. His rigid posture, clenched jaw, and fixed stare became their own confession. Then we turn to the evidence — the facts that exposed just how fragile Kohberger's “perfect plan” really was. The knife sheath with his DNA. The vehicle match. Cellphone data placing him near the home. Surveillance footage. The failed cover-up attempts. His unusual behavior in the days after the crime. Even Xana Kernodle's fight back, which may have left critical traces that sealed the case. Together, Tony and Robin show how both the emotional truth and the forensic truth converge: Kohberger wasn't the criminal mastermind he imagined. He wasn't in control. And on sentencing day, he couldn't hide from the families, the evidence, or himself. This episode isn't just commentary — it's behavioral and forensic analysis at full depth. If you want to understand why the case collapsed and why Alivea's statement hit him so hard, this is the breakdown you've been waiting for. #HiddenKillers #BryanKohberger #IdahoMurders #AliveaGoncalves #VictimImpactStatement #BehavioralAnalysis #TrueCrimePodcast #KohbergerSentencing #ForensicEvidence Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/@hiddenkillerspod Instagram https://www.instagram.com/hiddenkillerspod/ Facebook https://www.facebook.com/hiddenkillerspod/ Tik-Tok https://www.tiktok.com/@hiddenkillerspod X Twitter https://x.com/tonybpod Listen Ad-Free On Apple Podcasts Here: https://podcasts.apple.com/us/podcast/true-crime-today-premium-plus-ad-free-advance-episode/id1705422872

In this powerful Hidden Killers episode, we examine two sides of the same story: the forensic reality that dismantled Bryan Kohberger's image of intelligence — and the viral victim impact statement that attacked the last thing he had left: his ego. Host Tony Brueski and retired FBI Special Agent Robin Dreeke take you inside the psychology, behavior, and unraveling facade of a man who once believed he could outsmart everyone. First, we break down Alivea Goncalves' extraordinary statement — a surgical strike aimed directly at Kohberger's psychological pressure points. Her words didn't just describe loss. They deconstructed him. She went after his academic identity, his obsession with control, his need to be seen as superior. For someone built entirely around ego, this was a rare moment where the mask slipped. His rigid posture, clenched jaw, and fixed stare became their own confession. Then we turn to the evidence — the facts that exposed just how fragile Kohberger's “perfect plan” really was. The knife sheath with his DNA. The vehicle match. Cellphone data placing him near the home. Surveillance footage. The failed cover-up attempts. His unusual behavior in the days after the crime. Even Xana Kernodle's fight back, which may have left critical traces that sealed the case. Together, Tony and Robin show how both the emotional truth and the forensic truth converge: Kohberger wasn't the criminal mastermind he imagined. He wasn't in control. And on sentencing day, he couldn't hide from the families, the evidence, or himself. This episode isn't just commentary — it's behavioral and forensic analysis at full depth. If you want to understand why the case collapsed and why Alivea's statement hit him so hard, this is the breakdown you've been waiting for. #HiddenKillers #BryanKohberger #IdahoMurders #AliveaGoncalves #VictimImpactStatement #BehavioralAnalysis #TrueCrimePodcast #KohbergerSentencing #ForensicEvidence Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/@hiddenkillerspod Instagram https://www.instagram.com/hiddenkillerspod/ Facebook https://www.facebook.com/hiddenkillerspod/ Tik-Tok https://www.tiktok.com/@hiddenkillerspod X Twitter https://x.com/tonybpod Listen Ad-Free On Apple Podcasts Here: https://podcasts.apple.com/us/podcast/true-crime-today-premium-plus-ad-free-advance-episode/id1705422872

In this episode of Case Studies, Casey sits down with Andrew Smith, serial entrepreneur, multi-exit founder, and co-founder of Savory Fund, for an unforgettable deep dive into resilience, reinvention, and the sacred power of food.Andrew opens up about building three successful tech companies before the age of 33, selling to Fortune 100s, and navigating the dot-com bust and 2008 financial crisis. But it was a surprising pivot—supporting his wife Shauna's dream to open a Kneaders Bakery; that shifted his trajectory and ultimately led to launching a wildly successful F&B Investment firm.From selling streaming tech in the '90s to washing dishes in a café post-exit, Andrew shares raw lessons on humility, grit, and what it means to start over. They explore how family, faith, and a relentless drive to solve real problems shaped his entrepreneurial DNA, and why he believes restaurants are uniquely positioned to thrive, even in chaos.This conversation is a masterclass for founders on navigating ego, building with purpose, and finding meaning in the margins. Hosted on Acast. See acast.com/privacy for more information.

What if I told you you're already it?In this soul-awakening solo transmission, Dr. Samuel B. Lee, MD unpacks the deeper science and spirit of manifestation through the lens of eternal life wisdom, frequency embodiment, and quantum materialization. This isn't about the “law of attraction” as you've heard it. It's about becoming the frequency of what you seek—and remembering that what you seek is already seeking you.From revealing why traditional manifestation methods often fall short to decoding the sacred mechanics of the Kathara Grid, base pulse rhythm, and liquid light DNA, Dr. Lee takes us on a multidimensional deep dive into how eternal source energy flows—and how we can align with it to co-create a new reality from the inside out.This episode explores radical truths about identity, divine embodiment, and the true power of your scalar sound tones and water—the memory carrier of your eternal self.

Free Resource: My Content + Sales Simplification Crash Course is all yours. Click Here: https://www.karrieoutloud.com/content-simplification-crash-course

Sarah Swadling finds out about a quest to save our hidden cider orchard heritage using DNA testing.Work is being carried out in orchards to DNA fingerprint cider apple trees to identify varieties whose names died with the people who created them, or were never named. Keith Edwards, Professor of Crop Genetics at Bristol University, has been working with Devon cider-maker Barny Butterfield on the project. So far they've leaf sampled more than 10,000 trees on the hunt for DNA markers which aren't found in any of the national collections of apple trees, but are repeated in other historic cider orchards (so they're more significant than a lone tree grown from a pip). The aim: to secure the future of forgotten cider apple varieties, with the rediscovered trees being grown on from cuttings to preserve them for the future. Produced and presented by Sarah Swadling.

In this powerful Hidden Killers episode, we examine two sides of the same story: the forensic reality that dismantled Bryan Kohberger's image of intelligence — and the viral victim impact statement that attacked the last thing he had left: his ego. Host Tony Brueski and retired FBI Special Agent Robin Dreeke take you inside the psychology, behavior, and unraveling facade of a man who once believed he could outsmart everyone. First, we break down Alivea Goncalves' extraordinary statement — a surgical strike aimed directly at Kohberger's psychological pressure points. Her words didn't just describe loss. They deconstructed him. She went after his academic identity, his obsession with control, his need to be seen as superior. For someone built entirely around ego, this was a rare moment where the mask slipped. His rigid posture, clenched jaw, and fixed stare became their own confession. Then we turn to the evidence — the facts that exposed just how fragile Kohberger's “perfect plan” really was. The knife sheath with his DNA. The vehicle match. Cellphone data placing him near the home. Surveillance footage. The failed cover-up attempts. His unusual behavior in the days after the crime. Even Xana Kernodle's fight back, which may have left critical traces that sealed the case. Together, Tony and Robin show how both the emotional truth and the forensic truth converge: Kohberger wasn't the criminal mastermind he imagined. He wasn't in control. And on sentencing day, he couldn't hide from the families, the evidence, or himself. This episode isn't just commentary — it's behavioral and forensic analysis at full depth. If you want to understand why the case collapsed and why Alivea's statement hit him so hard, this is the breakdown you've been waiting for. #HiddenKillers #BryanKohberger #IdahoMurders #AliveaGoncalves #VictimImpactStatement #BehavioralAnalysis #TrueCrimePodcast #KohbergerSentencing #ForensicEvidence Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/@hiddenkillerspod Instagram https://www.instagram.com/hiddenkillerspod/ Facebook https://www.facebook.com/hiddenkillerspod/ Tik-Tok https://www.tiktok.com/@hiddenkillerspod X Twitter https://x.com/tonybpod Listen Ad-Free On Apple Podcasts Here: https://podcasts.apple.com/us/podcast/true-crime-today-premium-plus-ad-free-advance-episode/id1705422872

Da Katrine er otte år gammel, finder hun ud af, at manden hun kalder far, ikke er hendes biologiske far: hun er donorbarn. På en måde er det forbundet med skam – og derfor taler hun ikke om det. Hun gemmer det væk. Indtil hendes gode barndomsveninde Iben forærer hende en DNA-test i fødselsdagsgave. Iben er nemlig også donorbarn og har selv taget en test. I første omgang har Katrine ikke lyst, men til sidst kan hun ikke lade være. Og svaret kommer som et chok for Katrine. Det får hende til at tænke over alt det, hun ikke ved om sit biologiske ophav. Hvad nu hvis hun blev tiltrukket af en, hun er i familie med? Hvad nu hvis hun aldrig får at vide, at hun lider af en arvelig sygdom? De tanker er Katrine ikke alene med. De seneste år er diskussionen om anonyme sæddonorer vokset herhjemme. Og det har fået hende til at skrive et debatindlæg i Politiken om den tavshed og mangel på debat, der er om donorbørns rettigheder herhjemme. Hør Katrine Goli Jensen fortælle sin historie i dagens 'Du lytter til Politiken'.See omnystudio.com/listener for privacy information.

In this special end-of-year episode of Behind the Genes, host Sharon Jones is joined by Dr Rich Scott, Chief Executive Officer of Genomics England, to reflect on the past year at Genomics England, and to look ahead to what the future holds.  Together, they revisit standout conversations from across the year, exploring how genomics is increasingly embedded in national health strategy, from the NHS 10-Year Health Plan to the government's ambitions for the UK life sciences sector. Rich reflects on the real-world impact of research, including thousands of diagnoses returned to the NHS, progress in cancer and rare condition research, and the growing momentum of the Generation Study, which is exploring whether whole genome sequencing could be offered routinely at birth.  This episode offers a thoughtful reflection on how partnership, innovation, and public trust are shaping the future of genomic healthcare in the UK and why the years ahead promise to be even more exciting.  Below are the links to the podcasts mentioned in this episode, in order of appearance:  How are families and hospitals bringing the Generation Study to life? How can cross-sector collaborations drive responsible use of AI for genomic innovation? How can we enable ethical and inclusive research to thrive? How can parental insights transform care for rare genetic conditions? How can we unlock the potential of large-scale health datasets? Can patient collaboration shape the future of therapies for rare conditions? https://www.genomicsengland.co.uk/podcasts/what-can-we-learn-from-the-generation-study “There is this view set out there where as many as half of all health interactions by 2035 could be informed by genomics or other similar advanced analytics, and we think that is a really ambitious challenge, but also a really exciting one.”  You can download the transcript, or read it below. Sharon: Hello, and welcome to Behind the Genes.   Rich: This is about improving health outcomes, but it's also part of a broader benefit to the country because the UK is recognised already as a great place from a genomics perspective. We think playing our role in that won't just bring the health benefits, it also will secure the country's position as the best place in the world to discover, prove, and where proven roll out benefit from genomic innovations and we think it's so exciting to be part of that team effort.  Sharon: I'm Sharon Jones, and today I'll be joined by Rich Scott, Chief Executive Officer at Genomics England for this end of year special. We'll be reflecting on some of the conversations from this year's episodes, and Rich will be sharing his insights and thoughts for the year ahead. If you enjoyed this episode, we'd love your support, so please subscribe, rate, and share on your favourite podcast app. So, let's get started.  Thanks for joining me today, Rich. How are you?  Rich: Great, it's really good to be here.   Sharon: It's been a really exciting year for Genomics England. Can you tell us a bit about what's going on?  Rich: Yeah, it's been a really busy year, and we'll dive into a few bits of the components we've been working on really hard. One really big theme for us is it's been really fantastic to see genomics at the heart of the government's thinking. As we'll hear later, genomics is at the centre of the new NHS 10-year health plan, and the government's life sciences sector plan is really ambitious in terms of thinking about how genomics could play a role in routine everyday support of healthcare for many people across the population in the future and it shows a real continued commitment to support the building of the right infrastructure, generating the right evidence to inform that, and to do that in dialogue with the public and patients, and it's great to see us as a key part of that.  It's also been a really great year as we've been getting on with the various programmes that we've got, so our continued support of the NHS and our work with researchers accessing the National Genomic Research Library. It's so wonderful to see the continued stream of diagnoses and actionable findings going back to the NHS. It's been a really exciting year in terms of research, publications. In cancer, some really exciting publications on, for example, breast cancer and clinical trials. Really good partnership work with some industry partners, really supporting their work. For me, one of the figures we are always really pleased to see go up with time is the number of diagnoses that we can return thanks to research that's ongoing in the research library, so now we've just passed 5,000 diagnostic discoveries having gone back to the NHS, it really helps explain for me how working both with clinical care and with research and linking them really comes to life and why it's so vital.   And then, with our programmes, it's been great to see the Generation Study making good progress. So, working with people across the country, more than 25,000 families now recruited to the study, and we're beginning to hear about their experiences, including some of the families who've received findings from the programme. It's really nice to see and hear from Freddie's family, who talked to the press a bit about the finding that they received. Freddie was at increased risk of a rare eye cancer, and really pleasingly, it was possible to detect that early through the screening that was put in place. Again, it really brings to life why we're doing this, to make a difference and improve health outcomes.  Sharon: That's an incredible 12 months. Diving into that Generation Study piece and for listeners who don't know what that is, it's a research study in partnership with the NHS that aims to sequence the genomes of 100,000 newborn babies. On an episode from earlier in the year, we had mum, Rachel Peck, join the conversation, whose baby Amber is enrolled on a study. Let's year from Rachel now.  Rachel: From the parents' point of view, I guess that's the hardest thing to consent for in terms of you having to make a decision on behalf of your unborn child. But I think why we thought that was worthwhile was that could potentially benefit Amber personally herself or if not, there's the potential it could benefit other children.  Sharon: Consent has been such a big area of focus for us, Rich, and Rachel touches on that complexity, you know, making a decision on behalf of her unborn child. Can you talk a bit about our approach to consent in the Generation Study and what's evolving in that model?  Rich: Yeah. It's been for the whole study, really, starting out asking a really big question here, what we're aiming to do is generate evidence on whether and if so, how whole genome sequencing should be offered routinely at birth, and that's responding to a really ill need that we know that each year thousands of babies are born in the UK with treatable rare conditions. We will also need to see if whole genome sequencing can make a difference for those families, but we realise to do that, as with all screening, that involves testing more people than are going to benefit from it directly themselves. So, you have to approach it really sensitively. There's lots of complicated questions, lots of nuance in the study overall. One of them is thinking really carefully about that consent process so that families can understand the choices, they can understand the benefits and risks. This is still a research study. We're looking to understand whether we should offer this routinely. It's not part of routine care at this point. The evidence will help decision-makers, policymakers in the future decide that.  At the beginning of the programme, we spent a lot of time talking to families, talking to health professionals who understand the sorts of decisions that people are making at that time of life, but also are experts in helping think about how you balance that communication. That involved, as I say, a lot of conversations. We learnt a lot, lots of it practical stuff, about the stage of pregnancy that people are at when we first talk to them about the study, so that people aren't hurried and make this decision. What we've learnt in the study, right from the outset, is talking to people from midway through the pregnancy so that they really have time to engage in it and think about their choice. So, it's an important part of getting the study design right so that we run the study right. It's also a really crucial element of the evidence that will generate from the study so that we can understand if this is something that's adopted, how should we communicate about it to families. What would they want to know? What's the right level of information and how do we make that accessible in a way that is meaningful to people from different backgrounds, with different levels of interest, different accessibility in terms of digital and reading and so on. There's a lot that we've learnt along the way and there's a lot that we're still learning. And as I say, important things that we'll present as evidence later on.  Sharon: Thank you. It's fascinating there are so many moving parts and a lot to consider when you're building the design of a programme like this or study like this.  Earlier in the year you had a great conversation with Karim Beguir about the developments of AI in genomics. Let's revisit that moment.  Karim: We live in an extraordinary time. I want to emphasise the potential of scientific discovery in the next two or three years. AI is going to move, let's say, digital style technologies like coding and math towards more like science and biology. In particular, genomics is going to be a fascinating area in terms of potential.  Sharon: So, Karim talks about AI moving from maths and coding into biology. Why is genomics such a natural area for AI?  Rich: It's really fascinating. I think it links a lot to how we think about genomics and how you get the most value in terms of health benefit and sort of the progress that we can see could come through genomics more generally. So, your genome, which is your DNA code, written in 3 billion little letters across each one of us, one copied from mum, one copied from dad, even just our genomic code of one person is a large amount of data. That is just part of the story because we're not just interested in DNA for DNA's sake, this is about thinking about health and how we can improve health outcomes. So, it's also thinking about the other sorts of information that needs to link to genomic data to make a difference. Whether that's just to provide routine healthcare with today's knowledge, or whether it's about continuing to learn and discover.  As I mentioned at the beginning, I think a really important part of this whole picture is we've learnt a lot in the last 20/30/40 plus years about genomics. It's incredible how much progress has been made, and we're really just scratching the surface. Take rare disease and the progress that's been made there, it's wonderful how many more families we're able to help today. We know that many thousands of families we still can't find a diagnosis for when we know that there is one there for many of them. That theme of ongoing learning is at the centre of all of our work, and that will continue as we look about broader uses of genomics in other settings beyond rare conditions and cancer. It's also that ongoing learning, but also the amount of, at the moment, manual steps that are required in some of the processes that we need to, for example, find a diagnosis for someone or to make sure the tools that we use are the most up to date, the most up to date with the medical literature, for example. AI is a tool that we're, as the whole of the society, we're beginning to see how it can play a role. We see it as important today for some of the just really practical things. I mentioned it, staying up to date with the medical literature, making sure that we and our systems are aware of all of the knowledge that's coming in from around the world. It's got real potential there.  I think the biggest bottom line here is that it's got the potential to be a really important tool in terms of our ongoing learning and improvement. I'm a doctor by background, the human intelligence alone is fantastic, it's moved us a long way, but we know it also has tremendous blind spots. AI has the potential to complement us there. I guess another thing to really call out here, AI isn't a panacea, it's not suddenly going to answer all of the questions. And, just like human intelligence, it will have its own biases, have its own strong points, and less strong points.  One of the things we're really committed to is working with people like Karim, and many others, to understand where AI could make a difference, to test it, to generate evidence on how well it works and an understanding in all sorts of ways about how that might play out. And, make sure that as AI becomes a tool, that we in genomics, but also in other areas, we understand its strong points and where we need to be more careful and cautious with it. That's a really important part of what we're going to be doing in the coming years here, is making sure that we can maximise the impact of it, but also be confident, so that we can explain to people whose data we might use it on how we're doing it and what it's bringing.  Sharon: Thanks Rich. It's definitely a fast-moving conversation of which we really want to be part of. One of the things that's come up again and again this year is participation and co-production. Let's hear quote that really captures that.  Bobbie: In an earlier conversation with Paul, which you might find surprising that it's stuck with me so much, he used the word ‘extractive'. He said that he'd been involved in research before and looking back on it, he had felt at times it could be a little bit extractive. You come in, you ask questions, you take the data away and analyse it, and it might only be by chance that the participants ever know what became of things next. One of the real principles of this project was always going to be co-production and true collaboration with our participants.  Sharon: That was Professor Bobbie Farsides talking about moving away from extractive research towards true co-production. How are we making that shift in practice here at Genomics England?  Rich: It's a great question. It's one of the areas where I think we've learnt most as an organisation over the years about how really engaging from the beginning with potential participants in programmes, participants who join our programmes, people who are involved in delivering our programmes and healthcare is so important at the beginning. I mentioned earlier the work to think about the consent process for the Generation Study, and that's one of the areas where I think from our first programme, 100,000 Genomes Project, we learnt a lot about how to do that well, some of the pitfalls, some of the bits that are most challenging. And really, right from the start of our programmes, making sure that people who will potentially benefit from the programmes, potentially join them, can be part of that engagement process, and really part of the design and the shaping of the research questions, the parameters around research, but also the materials and how people will engage with them. And that's one of the key capabilities we have internally as an organisation, so we work with partners externally, but also it's a really key part of the team that we have at Genomics England.  Sharon: So, whilst Bobbie talked about moving away from research that can feel one-sided and towards true collaboration, in another episode, Lindsay, a parent of a child with a rare condition, reflected on what that change really means for families and how it's empowering to see their voices and experiences shaping future treatments.  Lindsay: Historically, there's been a significant absence of a patient voice in rare disease research and development. And knowing that that's changing, I think that's really empowering for families. To know that professionals and industry are actually listening to our stories and our needs and really trying to understand, that offers much greater impact on the care and treatments of patients in the future.  Sharon: So, what role do you see participants as partners in shaping the next phase of Genomics England's work?  Rich: So, as you probably detected from my last answer, we see it as absolutely vital. One of the really exciting things here at Genomics England, we've had a participant panel from very early in our life as an organisation. That's one really important route to us at the heart of our organisation, part of our governance, making sure that participants representing all sorts of parts of our programme, but rare conditions being a really large focus for us. And I think, what's so striking as someone with a medical and a research background can see how I think historically medics and researchers have sometimes not known, sort of maybe been a bit scared about knowing how to involve participants from the outset. Often, because they're worried that they might ask the wrong questions in the wrong way, they just don't have the tools.   One of the things I often say now to people we work with is one of the most empowering and positive experiences we have at Genomics England is the power of our participants helping to, right from the beginning, shape what the questions are that we should be asking. Realise some of the challenges that you can't possibly, if you're not in their shoes, understand are the most important to really shape how we prioritise our work internally, the problems that we need to solve first, how we think about some of the practical impacts on people's lives that, again, without hearing from their voice you just wouldn't know. And again, to help our researchers, people accessing data in the National Genomic Research Library, helping them make sure that they involve participants in their work and the confidence and tools to do that.  Sharon: That's great, thank you. Another big theme this year has been collaboration across the NHS, academia, and industry. Dr Raghib Ali puts this really well.  Raghib: There are areas where academia and the NHS are very strong, and there are areas where industry is very strong, and why working together, as we saw, you know, very good examples during the pandemic with the vaccine and diagnostic tests, etc., a collaboration between the NHS, academia, and industry leads to much more rapid and wider benefits for our patients and, hopefully, in the future for the population as a whole in terms of early detection and prevention of disease.  Sharon: So, how does collaboration fit into the 10-year health plan and what's next for 2026 in that space, Rich?  Rich: I think one of the most enjoyable parts of my role at Genomics England and our role as an organisation is the fact that we see ourselves very much as part of a, sort of team across the UK and in fact internationally in terms of delivering on the potential we see for genomics. So, we have a vision as an organisation, which has been the same the last 5 or so years, which is a world where everyone can benefit from genomic healthcare. In fact, that vision is now shared by the NHS from a genomics perspective, and really demonstrably, the 2 parts of the system absolutely pointing in the same direction. And when we've been thinking, looking forward with that 10-year lens on it, what we always like to do, and I think it's a real privilege to be able to do, because we're here in the UK, because we have a National Health Service, because there's been that long-term commitment from government on genomics and really taking a long-term investment view there, and because of so many other parts of the ecosystem, other experts who access data in the National Genomic Research Library, research organisations like Our Future Health, UK Biobank, all teaming together, and the expertise that's there in genomics more broadly. So we've, if you like, worked back from what the UK could do as whole, and in the 10-year health plan, as I said earlier, genomics is at the heart of that.  There's a double helix on the front cover and, in fact, on the watermark on almost every page. And, there's this view set out there where as many as half of all health interactions by 2035 could be informed by genomics or other similar advanced analytics. And we think that that's a really ambitious challenge. We see a really important role for us, as Genomics England, in contributing to that, but it's very much a team effort. Our role is around where we have the biggest capabilities, so around building and running digital infrastructure at a national scale for healthcare delivery and for research, to building evidence to inform future policies, so running programmes like the Generation Study to inform future policy. And really, as part of that, that evidence piece, being driven by engagement, ethics, and work on equity, to really make sure that evidence that future policy can be built on is informed by a fully rounded view. We think if we do that right that we could as a country with others, the NHS, research organisations, many others could live up to that ambition that's set out there in the 10-year plan.   And the 10-year plan is really clear, and government is really clear that this is about improving health outcomes. But it's also part of a broader benefit to the country because the UK is recognised already as a great place from a genomics perspective. We think playing our role in that won't just bring the health benefits, it also will secure the country's position as the best place in the world to discover, prove and where proven role out benefit from genomic innovations. And we think it's so exciting to be part of that team effort.  Sharon: So, Genomics England's refreshed mission and direction of travel is really setting out how we move from research to routine care, and how we embed genomics across the health system. Carlo Rinaldi captured the idea perfectly, imagining a future where diagnosis and hope arrive hand in hand.  Carlo: My dream is that in five to ten years' time an individual with a rare disease is identified in the clinic, perhaps even before symptoms have manifested. At that exact time the day of the diagnosis becomes also a day of hope, in a way, where immediately the researcher, the genetic labs, flags that specific variant, that specific mutation. We know exactly which is the best genetic therapy to go after.   Sharon: And Rich, what are your thoughts on that?  Rich: I think Carlo captures it really well. And for us, I think a really big theme is for that potential for genomics to make a difference, a continued and in fact increased difference for people with rare conditions and cancer, areas where it's already making a difference, but also with the potential to make a much broader impact for people across the population. The real theme is embedding genomics into routine care, making it something that you don't need to know that you're seeing an expert in genomics to benefit from it, really make sure that those benefits can be felt as just part of routine care. It's not something separate where we recognise that the best healthcare is healthcare that's supported by all sorts of inputs, with genomics being a key part of that, and that we can continue to learn as we do that. So that with people's consent, with their understanding of how their data is being used, we know that if we don't have the best answer for them today, we give the best answer we can today, and we can continue to learn, and they can benefit from that in the future.   I'm a rare disease doctor by background, and one of the really most enjoyable parts of my job is seeing that come to practice. In the last year or so I've had a number of families where I've been seeing the family for years, and a researcher accessing data in the National Genomic Research library has found an answer that we've not been able to find for maybe their child's whole life, and then finally we're able to feed it back. Seeing that come to life is just so wonderful, and I think gives us a bit of a blueprint for how things could work more generally.  Sharon: That's great. I mean, what a feeling for those families who do get those answers. As we look ahead to 2026 and beyond, the conversation is starting to include prevention, using genomics not just to diagnose conditions but to predict and treat and even prevent them. Alice Tuff-Lacey summarised this nicely in an episode about Generation Study.  Alice: This is quite an exciting shift in how we use whole genome sequencing, because what we're talking about is using it in a much more preventative way. Traditionally where we've been using it is diagnostically where we know someone's sick and they've got symptoms of rare condition, and we're looking to see what they might have. What we're actually talking about is screening babies from birth using their genome to see if they're at risk of a particular condition. And what this means is this raises quite a lot of complex ethical, operational, and scientific and clinical questions.  Sharon: Rich, when you think about 2026, what's your biggest hope for where we'll be this time next year?  Rich: I think it's a really exciting time. As you can tell from how we've been speaking, I'm really excited about the direction of travel and how over the next 5 and 10 years we can really make a transformational shift because of how well placed we are in the UK from a genomics perspective. Where we are with today's knowledge, where we could be because of the continued government and NHS commitment to genomics being at the heart of this, if we build the right infrastructure, if we generate the right evidence to inform what's adopted, I think we're in a really exciting place.  From a 2026 perspective, I think what we're really committed to is continuing to do the work, the day-by-day-by-day work that is to build that incrementally. So, a really big focus for us is continuing to support the NHS and making sure researchers can access data, so that flow of answers for families can continue and grow, accelerate, to continue delivering the Generation Study because it's a really important part of that wider jigsaw to generate the evidence that can inform future policy on whether this is something that's adopted and offered routinely to every child when they're born.  I think a really important time now that the government's provided the opportunity for us as a team, as a UK genomics and life sciences ecosystem, is to really put in place some of the next steps, the building blocks that can take us towards that 10-year vision. So for us also, a really important part of the year is beginning the design process for an adult population genomics programme, where we're looking at what evidence it's important that we can provide that's complementary to different work around by others in the ecosystem that needs to be there if we're going to think about that potential broader use of genomics.  Sharon: That's great. It sounds like another exciting year ahead. So, we're going to wrap up there. Thank you to Rich Scott for sharing your reflections on the key milestones this year, and for your thoughts on the year ahead. Thanks, Rich.  Rich: Thanks very much for having me.  Sharon: If you enjoyed today's episode, we'd love your support, so please subscribe, share, and rate us on wherever you listen to your podcasts. I've been your host, Sharon Jones. This podcast was produced by Deanna Barac and edited by Bill Griffin at Ventoux Digital. Thank you for listening. 

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of fascinating stories that underscore the dynamic nature of our industry, where scientific innovation meets real-world application.Starting with a significant advancement in gene therapy, researchers have made remarkable progress in a novel approach to treating rare genetic disorders. This new methodology involves the use of CRISPR technology to edit genes directly within the human body, paving the way for potential cures once thought impossible. By targeting specific DNA sequences, scientists can now correct genetic mutations at their source. This breakthrough not only promises to transform the treatment landscape for rare diseases but also enhances our understanding of genetic disorders at a molecular level. The implications here extend beyond rare conditions, potentially offering new avenues for tackling more common genetic diseases in the future.Moving forward, let's discuss recent regulatory developments that have caught the industry's attention. The FDA has granted accelerated approval to a new oncology drug that shows promise in treating advanced forms of breast cancer. This decision was based on compelling clinical trial results demonstrating significant improvements in patient survival rates compared to existing therapies. The drug targets specific proteins involved in tumor growth, offering a more precise treatment option with potentially fewer side effects. This approval exemplifies how regulatory bodies are adapting to expedite access to life-saving treatments while ensuring rigorous safety and efficacy standards.In another noteworthy development, a Phase III clinical trial has yielded positive results for a novel Alzheimer's drug. The trial demonstrated that this drug significantly slows cognitive decline in patients with early-stage Alzheimer's disease. By targeting amyloid plaques in the brain, which are believed to contribute to neurodegeneration, this therapeutic approach represents a potential shift in how we treat this debilitating condition. These findings provide hope for millions affected by Alzheimer's and underscore the importance of continued investment in neuroscience research.Turning our attention to infectious diseases, there's exciting news from a biotech company focusing on vaccine development. They've announced encouraging preliminary data from trials of their new mRNA-based vaccine for respiratory syncytial virus (RSV). RSV is known for causing severe respiratory illness, particularly in infants and the elderly. The vaccine demonstrated robust immune responses and a favorable safety profile, suggesting it could become an important tool in preventing RSV infections globally. This development highlights the versatility of mRNA technology, which has already revolutionized COVID-19 vaccine design and holds promise for addressing various infectious diseases.In terms of industry trends, one cannot overlook the growing emphasis on personalized medicine. Recent advancements in biomarker research are enabling more tailored therapeutic approaches across multiple disease areas. By identifying specific genetic or molecular markers associated with diseases, healthcare providers can better predict patient responses to certain treatments. This shift towards precision medicine not only improves patient outcomes but also enhances healthcare efficiency by reducing trial-and-error prescribing.Lastly, we delve into an intriguing area of metabolic disorders where innovative therapeutic strategies are emerging. A biotech firm has developed a first-in-class oral medication for treating non-alcoholic steatohepatitis (NASH), a serious liver condition linked to obesity and metabolic syndrome. The drug works by modulating key metabolic pathways involved in liver inflammation and fibrSupport the show

Christine Platt and Alex Elle engage in a profound dialogue surrounding Platt's latest publication, "Less is Liberation." Central to this conversation is the assertion that true liberation transcends mere physical possessions; it embodies a fundamental shift in mindset and identity. As they explore the intricate relationship between personal storytelling and broader social consciousness, they emphasize the need for individuals, particularly women, to prioritize their well-being and to redefine selfishness as a necessary act of self-care. The discussion delves into the challenges of navigating societal expectations and the importance of emotional honesty in the journey toward self-discovery. Throughout this intimate author signing and book talk, both authors illuminate the transformative power of literature as a means of fostering community and healing.Takeaways:Christine Platt's book, 'Less is Liberation', intertwines personal narratives with themes of social consciousness.The authors emphasize the necessity of prioritizing self-care and recognizing one's own needs.During the talk, the importance of community and healing through literature is highlighted as a recurring theme.Both authors reflect on the journey of redefining selfishness and the impact of societal expectations on personal identity.The discussion addresses the emotional challenges women face, particularly in navigating roles and responsibilities.Platt articulates that true liberation is a continuous process rather than a fixed destination.Call to ActionEx. Tune in each month and subscribe to our newsletter to stay engaged with the conversation.)Book Discussed: Less is LiberationLinks to follow:https://www.instagram.com/mahoganybookshttps://www.instagram.com/mahoganybookspodcastnetworkPodcast Credits:Video & Audio: Shed Life ProductionsProduction: The Trap Factory StudioMentioned in this episode:African AncestryWe are the pioneers of genetic ancestry tracing for Black people globally, reconnecting you to your specific African roots–the country and the people. Our scientists compare your DNA markers to the largest African reference database in the world in order to find your African origin up to 2000 years ago.African AncestryPre-Order The Seven Daughters of Dupree  Nikisha Elise Williams, the host of the Black and Published podcast, is celebrating the release of her forthcoming novel, The Seven Daughters of Dupree. This historical fiction novel is about the secrets kept between mothers and daughters over the course

In 1983, Susan Tice, a 45-year-old mother of four was found raped and stabbed to death in her Toronto home. Four months later, across town, 22-year-old Erin Gilmour returns home from work and is attacked the same way. The women didn't know each other, and both cases remained unsolved for decades. In 2000, DNA profiles from each crime proved their attacker was the same man – but didn't reveal his identity. It would take another 20 years, but thanks to genetic genealogy research, the killer was arrested, charged and convicted, bringing a measure of closure for the victims' families. Premiered May 10, 2024 For more info, please go to ⁠https://globalnews.ca/tag/crime-beat/⁠ Subscribe to Crime Beat TV HERE: ⁠https://youtu.be/6h7V1agmcoQ?si=c3aAa9tsAa3drLky ⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

The calls are pouring in and Packer fans are fed up. Tonight's episode dives deep into the raw frustration consuming the fanbase as the season spirals toward what feels like an inevitable playoff disappointment. Craig from Indiana kicks things off with his top five reasons this season has been so devastating, from the joy-killing injuries to the perpetual special teams disasters. Then Jersey Mike drops a truth bomb that sparks the night's biggest debate: Is Matt LaFleur too much of a "nerd coach" to inspire this team when things get ugly? The callers don't hold back comparing him to Dan Campbell's fire-breathing leadership style, and the conversation gets heated about what's really missing in Green Bay's DNA. Packer Super Fan Mike brings the receipts on Lambeau's vanishing home field advantage, revealing a stat that will make your blood boil about how many home games we've lost compared to the Holmgren era. Plus, the Malik Willis versus Jordan Love debate continues, and Ryan draws a hard line in the sand about Week 18 starter decisions. This episode is brought to you by PrizePicks! Use code PACKDADDY to get started with America's #1 fantasy sports app. https://prizepicks.onelink.me/LME0/PACKDADDY To advertise on this podcast please email: ad-sales@libsyn.com Or go to: https://advertising.libsyn.com/packernetpodcast Help keep the show growing and check out everything I'm building across the Packers and NFL world: Support: Patreon: www.patreon.com/pack_daddy Venmo: @Packernetpodcast CashApp: $packpod Projects: Grade NFL Players ➜ fanfocus-teamgrades.lovable.app Packers Hub ➜ packersgames.com Create NFL Draft Big Boards ➜ nfldraftgrades.com Watch Draft Prospects ➜ draftflix.com Screen Record ➜ pause-play-capture.lovable.app Global Economics Hub ➜ global-economic-insight-hub.lovable.app

If you could stretch out the DNA in just one of your cells, it would be six feet long! And yet, it fits inside a space smaller than the tip of a needle and knows exactly what to do to make you… you! The secret is how it’s folded. Inside each cell, DNA is arranged in a stunning three-dimensional structure that helps control how life functions. This intricate 3-D design determines how genes are expressed, how the body adapts to change, and what makes each person unique. This level of precision and order doesn’t happen by accident. It points to a Creator whose design reaches deep into every detail of life. Human Origins: https://store.icr.org/human-origins.html Chimps and Humans: https://store.icr.org/chimps-and-humans.html --- Join ICR's YouTube channel to get access to perks Join us on Patreon

In this powerful breakdown of the Gilgo Beach case, Tony Brueski and retired FBI Special Agent Jennifer Coffindaffer take listeners inside the evidence story prosecutors will present to a single jury—now that a judge has ruled all seven murder charges against Rex Heuermann will be tried together. This ruling reshapes the entire strategy on both sides of the courtroom, giving the state a sweeping narrative arc while handing the defense the ammunition to argue prejudice, jury overload, and unfair consolidation. We begin with the evidence tour: the infamous large doll, the cage, the secret room, the basement storage vault, and the forensic haul investigators collected during the search warrant execution. Coffindaffer walks through how prosecutors will try to connect these items to time, transfer, and intent—and why the defense will insist none of it is meaningful unless tied to scientifically grounded timelines and corroboration. The rule is simple: seized items aren't guilt until they're connected to the crime. Then we dive into the science. Whole genome hair sequencing may be “new to this courtroom,” but it's not new to forensic research. The state will rely on validation studies and conservative conclusions; the defense will call it junk science. This battle could determine whether key DNA evidence even makes it to the jury box. We also explore the family factor: could Heuermann's daughter testify? Would Asa Ellerup take the stand? And how would their emotional presence—or absence—shape juror perception? Finally, former prosecutor and defense attorney Eric Faddis breaks down the legal stakes of joinder: seven counts, one jury, decades of alleged conduct, and a trial timeline stretching realistically toward 2027. This isn't just strategy—it's a marathon requiring clean science, disciplined storytelling, and a jury willing to follow every step. This is the full picture: the evidence, the science, the strategy, and the stakes. #RexHeuermann #GilgoBeach #HiddenKillers #DNAEvidence #ForensicScience #JenniferCoffindaffer #EricFaddis #TrueCrimeNews #SerialKillerTrial #TonyBrueski Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/@hiddenkillerspod Instagram https://www.instagram.com/hiddenkillerspod/ Facebook https://www.facebook.com/hiddenkillerspod/ Tik-Tok https://www.tiktok.com/@hiddenkillerspod X Twitter https://x.com/tonybpod Listen Ad-Free On Apple Podcasts Here: https://podcasts.apple.com/us/podcast/true-crime-today-premium-plus-ad-free-advance-episode/id1705422872

In this episode of Hidden Killers Live, we confront two of the most alarming cracks in the Delphi murder case: the collapsing appeal process for Richard Allen and the investigative leads that were sidelined long before this case ever reached a jury. With defense attorney and Defense Diaries host Bob Motta joining the panel, we break down how missing exhibits tied to the controversial 136-page Franks memo were never transmitted into the certified trial record — including documents referencing alternate suspects and investigative inconsistencies. Without those materials, the appellate court is reviewing an incomplete case file, forcing Allen's team to file motions just to keep the appeal from dying on procedural grounds. But the structural failure doesn't end with clerical chaos. Newly surfaced depositions reveal investigators explaining why certain suspects connected to symbolic crime-scene elements and the so-called “Odinism angle” were labeled “no further action.” One individual made a startling comment about whether his DNA would be found on the victims. Another posted imagery that resembled aspects of the crime scene and owned a .40-caliber handgun that was never seized or tested. These aren't fringe theories — they're sworn statements about leads that were never fully explored. Bob and I examine how narrative lock, investigative pressure, and institutional bias can steer an entire case toward a single suspect while sidelining red flags that demanded deeper scrutiny. And now, those decisions may come back to haunt the state as the appeal heads toward a legal battlefield built on missing records, disputed evidence, and a procedural mess that raises questions about the system's capacity to deliver justice at all. If you want to understand the investigative blind spots and bureaucratic failures shaping the future of the Delphi case, this is the episode that puts everything on the table. #DelphiMurders #RichardAllen #DelphiCase #FranksMemo #TrueCrimeAnalysis #InvestigativeFailures #HiddenKillers #BobMotta #AppealProcess #JusticeSystem Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/@hiddenkillerspod Instagram https://www.instagram.com/hiddenkillerspod/ Facebook https://www.facebook.com/hiddenkillerspod/ Tik-Tok https://www.tiktok.com/@hiddenkillerspod X Twitter https://x.com/tonybpod Listen Ad-Free On Apple Podcasts Here: https://podcasts.apple.com/us/podcast/true-crime-today-premium-plus-ad-free-advance-episode/id1705422872

In this episode of Hidden Killers Live, we confront two of the most alarming cracks in the Delphi murder case: the collapsing appeal process for Richard Allen and the investigative leads that were sidelined long before this case ever reached a jury. With defense attorney and Defense Diaries host Bob Motta joining the panel, we break down how missing exhibits tied to the controversial 136-page Franks memo were never transmitted into the certified trial record — including documents referencing alternate suspects and investigative inconsistencies. Without those materials, the appellate court is reviewing an incomplete case file, forcing Allen's team to file motions just to keep the appeal from dying on procedural grounds. But the structural failure doesn't end with clerical chaos. Newly surfaced depositions reveal investigators explaining why certain suspects connected to symbolic crime-scene elements and the so-called “Odinism angle” were labeled “no further action.” One individual made a startling comment about whether his DNA would be found on the victims. Another posted imagery that resembled aspects of the crime scene and owned a .40-caliber handgun that was never seized or tested. These aren't fringe theories — they're sworn statements about leads that were never fully explored. Bob and I examine how narrative lock, investigative pressure, and institutional bias can steer an entire case toward a single suspect while sidelining red flags that demanded deeper scrutiny. And now, those decisions may come back to haunt the state as the appeal heads toward a legal battlefield built on missing records, disputed evidence, and a procedural mess that raises questions about the system's capacity to deliver justice at all. If you want to understand the investigative blind spots and bureaucratic failures shaping the future of the Delphi case, this is the episode that puts everything on the table. #DelphiMurders #RichardAllen #DelphiCase #FranksMemo #TrueCrimeAnalysis #InvestigativeFailures #HiddenKillers #BobMotta #AppealProcess #JusticeSystem Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/@hiddenkillerspod Instagram https://www.instagram.com/hiddenkillerspod/ Facebook https://www.facebook.com/hiddenkillerspod/ Tik-Tok https://www.tiktok.com/@hiddenkillerspod X Twitter https://x.com/tonybpod Listen Ad-Free On Apple Podcasts Here: https://podcasts.apple.com/us/podcast/true-crime-today-premium-plus-ad-free-advance-episode/id1705422872

In this powerful breakdown of the Gilgo Beach case, Tony Brueski and retired FBI Special Agent Jennifer Coffindaffer take listeners inside the evidence story prosecutors will present to a single jury—now that a judge has ruled all seven murder charges against Rex Heuermann will be tried together. This ruling reshapes the entire strategy on both sides of the courtroom, giving the state a sweeping narrative arc while handing the defense the ammunition to argue prejudice, jury overload, and unfair consolidation. We begin with the evidence tour: the infamous large doll, the cage, the secret room, the basement storage vault, and the forensic haul investigators collected during the search warrant execution. Coffindaffer walks through how prosecutors will try to connect these items to time, transfer, and intent—and why the defense will insist none of it is meaningful unless tied to scientifically grounded timelines and corroboration. The rule is simple: seized items aren't guilt until they're connected to the crime. Then we dive into the science. Whole genome hair sequencing may be “new to this courtroom,” but it's not new to forensic research. The state will rely on validation studies and conservative conclusions; the defense will call it junk science. This battle could determine whether key DNA evidence even makes it to the jury box. We also explore the family factor: could Heuermann's daughter testify? Would Asa Ellerup take the stand? And how would their emotional presence—or absence—shape juror perception? Finally, former prosecutor and defense attorney Eric Faddis breaks down the legal stakes of joinder: seven counts, one jury, decades of alleged conduct, and a trial timeline stretching realistically toward 2027. This isn't just strategy—it's a marathon requiring clean science, disciplined storytelling, and a jury willing to follow every step. This is the full picture: the evidence, the science, the strategy, and the stakes. #RexHeuermann #GilgoBeach #HiddenKillers #DNAEvidence #ForensicScience #JenniferCoffindaffer #EricFaddis #TrueCrimeNews #SerialKillerTrial #TonyBrueski Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/@hiddenkillerspod Instagram https://www.instagram.com/hiddenkillerspod/ Facebook https://www.facebook.com/hiddenkillerspod/ Tik-Tok https://www.tiktok.com/@hiddenkillerspod X Twitter https://x.com/tonybpod Listen Ad-Free On Apple Podcasts Here: https://podcasts.apple.com/us/podcast/true-crime-today-premium-plus-ad-free-advance-episode/id1705422872